問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林敬業

Recruiting

List

33Cases

2018-09-01 - 2026-10-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-10-30 - 2026-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-02-01 - 2026-11-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
8Sites

Recruiting8Sites

2018-11-22 - 2021-10-26

Phase II

Completed
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response

  • Condition/Disease

    Chronic myeloid leukemia(CML)

  • Test Drug

    ABL001, GLIVEC (STI571), Tasigna (AMN107)

Participate Sites
3Sites

Recruiting3Sites

2020-01-03 - 2022-03-21

Phase III

Completed
A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A

  • Condition/Disease

    Severe Hemophilia A

  • Test Drug

    BIVV001( rFVIIIFc-VWF-XTEN)

Participate Sites
2Sites

Recruiting2Sites

2022-07-01 - 2028-05-31

Phase III

Active
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    BMS-986213 (Relatlimab-Nivolumab FDC)

Participate Sites
5Sites

Recruiting5Sites

2020-04-01 - 2026-09-01

Phase I/II

Active
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Healthy Volunteers and Patients with Hemophilia A

  • Condition/Disease

    Hemophilia A

  • Test Drug

    NXT007

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2023-03-16

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    PF-06838435 (Fidanacogene elaparvovec)

Participate Sites
2Sites

Recruiting2Sites

2021-11-17 - 2030-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB